Lead Product(s) : Undisclosed
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Preclinical
Sponsor : Innovate Biopharmaceuticals
Deal Size : $4.5 million
Deal Type : Funding
Details : This grant will fund a £3.2 million project to further develop Rinri’s novel stem cell therapy to reverse sensorineural hearing loss (SNHL) an area / a condition where there remains a significant global unmet need.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 13, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Preclinical
Sponsor : Innovate Biopharmaceuticals
Deal Size : $4.5 million
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Preclinical
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $14.1 million
Deal Type : Financing
Details : The proceeds will support the development of the Company's novel stem cell therapy to reverse sensorineural hearing loss (SNHL).
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 20, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Preclinical
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $14.1 million
Deal Type : Financing